IN THE CLAIMS:

In accordance with 37 C.F.R. § 1.121, please substitute for claims 8, 12, 14, and 15 the following rewritten version of the same claims, as amended. The changes are shown explicitly in the attached "Version with Markings to Show Changes Made".

8. (Amended) A method of identifying one or more indolinone compounds of Formula I

C1

(I) 

that inhibit growth factor-stimulated cell proliferation comprising the following steps:

(a) contacting cells with one or more indolinone compounds;

(b) contacting said cells with one or more growth factors selected from the group consisting of VEGF, PDGF, and FGF;

(c) monitoring an inhibitory effect on growth factor stimulated cell proliferation; and

(d) identifying indolinone compounds of formula I that inhibit growth factor-stimulated cell proliferation.

C2

12. (Amended) A method of identifying one or more indolinone compounds of Formula I



(I)

C2 Cont.

that are active in an adjuvant arthritis model in rats comprising the following steps:

(a) administering said one or more indolinone compounds to said rats;

(b) monitoring an effect upon general disease symptoms in said rats; and

(c) identifying indolinone compounds of formula I that are active in an adjuvant arthritis model in rats.

C3

14. (2X Amended) A method of modulating abnormal cell proliferation, comprising administering to a patient in need of such treatment a composition comprising a therapeutically effective amount of one or more compounds of formula I,

wherein said composition optionally includes one more pharmaceutically acceptable excipients in at least one of parenteral, oral, or topical formulation:

SUB D1



(I)

wherein,

R_1 is H or alkyl;

R_2 is O or S;

R_3 is H;

R_4, R_5, R_6, and R_7 are each independently selected from the group consisting of hydrogen alkyl, alkoxy, aryl, aryloxy, alkaryl, alkaryloxy, halogen, trihalomethyl, S(O)R, SO_2NRR', SO_3R, SR, NO_2, NRR', OH, CN, C(O)R, OC(O)R, NHC(O)R, $(CH_2)_nCO_2R$, CONRR', and $(CH_2)_nONRR'$;

A is selected from the group consisting of 4,5,6,7-tetrahydroindole, thiophene, pyrrole, pyrazole, imidazole, 1,2,3-triazole, 1,2,4-triazole, oxazole, isoxazole, thiazole, isothiazole, 2-sulfonylfuran, 4-alkylfuran, 1,2,3-oxadiazole, 1,2,4-oxadiazole, 1,2,5-oxadiazole, I ,3,4-oxadiazole, I ,2,3,4,-oxatriazole, 1,2,3,5-oxatriazole, 1 ,2,3-thiadiazole, 1 ,2,4-thiadiazole, I ,2,5-thiadiazole, 1,3,4-thiadaizole, 1,2,3 ,4-thiatriazole, 1,2,3,5-thiatriazole, and tetrazole, wherein said group is optionally substituted with one or more substituents selected from the group consisting of alkyl, alkoxy, aryl, aryloxy, alkaryl, alkaryloxy, halogen, trihalomethyl, S(O)R, SO_2NRR', SO_3R, SR, NO_2, NRR', OH, CN, C(O)R, OC(O)R, NHC(O)R, $(CH_2)_nCO_2R$, CONRR', and $(CH_2)_nONRR'$;

n is 0-3;

R is selected from the group consisting of H, alkyl, and aryl; and

R' is selected from the group consisting of H, alkyl, and aryl, wherein said alkyl is optionally substituted with a six-membered heteroaliphatic ring, and wherein said six-membered ring is optionally substituted at one or more positions with substituents selected from the group consisting of alkyl, alkoxy, halogen, trihalomethyl, NO_2, and $(CH_2)_nCO_2R$.

15. (2X Amended) A method of treating or preventing an abnormal condition by administering to a patient in need of such treatment a pharmaceutically acceptable composition comprising a therapeutically effective amount of one or more compounds of formula I,

wherein said abnormal condition is selected from the group consisting of arthritis, endometriosis, ocular neovascularization, solid tumor growth and metastases, and excessive

scarring during wound healing, wherein said composition optionally includes one or more pharmaceutically acceptable excipients in at least one of parenteral, oral, or topical formulation:

(I) 

wherein,

C3
cont

R_1 is H or alkyl;

R_2 is O or S;

R_3 is H;

R_4, R_5, R_6, and R_7 are each independently selected from the group consisting of hydrogen alkyl, alkoxy, aryl, aryloxy, alkaryl, alkaryloxy, halogen, trihalomethyl, S(O)R, SO_2NRR', SO_3R, SR, NO_2, NRR', OH, CN, C(O)R, OC(O)R, NHC(O)R, $(CH_2)_nCO_2R$, CONRR', and $(CH_2)_nONRR'$;

A is selected from the group consisting of 4,5,6,7-tetrahydroindole, thiophene, pyrrole, pyrazole, imidazole, 1,2,3-triazole, 1,2,4-triazole, oxazole, isoxazole, thiazole, isothiazole, 2-sulfonylfuran, 4-alkylfuran, 1,2,3-oxadiazole, 1,2,4-oxadiazole, 1,2,5-oxadiazole, I ,3,4-oxadiazole, I ,2,3,4,-oxatriazole, 1,2,3,5-oxatriazole, 1 ,2,3-thiadiazole, 1 ,2,4-thiadiazole, I ,2,5-thiadiazole, 1,3,4-thiadaizole, 1,2,3 ,4-thiatriazole, 1,2,3,5-thiatriazole, and tetrazole, wherein said group is optionally substituted with one or more substituents selected from the group consisting of alkyl, alkoxy, aryl, aryloxy, alkaryl, alkaryloxy, halogen, trihalomethyl, S(O)R, SO_2NRR', SO_3R, SR, NO_2, NRR', OH, CN, C(O)R, OC(O)R, NHC(O)R, $(CH_2)_nCO_2R$, CONRR', and $(CH_2)_nONRR'$;

n is 0-3;

C3 cont

R is selected from the group consisting of H, alkyl, and aryl; and

R' is selected from the group consisting of H, alkyl, and aryl, wherein said alkyl is optionally substituted with a six-membered heteroaliphatic ring, and wherein said six-membered ring is optionally substituted at one or more positions with substituents selected from the group consisting of alkyl, alkoxy, halogen, trihalomethyl, NO_2, and $(CH_2)_nCO_2R$.

Please add the following newly added claims.

16. (NEW) A method of inhibiting VEGF, FGF, or PDGF stimulated cell proliferation in vein endothelial cells or smooth muscle cells *in vivo*, comprising administering to a patient in need of such treatment a composition comprising a therapeutically effective amount of said one more compounds of formula I,

wherein said composition optionally includes one more pharmaceutically acceptable excipients in at least one of parenteral, oral, or topical formulation:

C4

(I) 

wherein,

R_1 is H or alkyl;

R_2 is O or S;

R_3 is H;

R_4, R_5, R_6, and R_7 are each independently selected from the group consisting of hydrogen alkyl, alkoxy, aryl, aryloxy, alkaryl, alkaryloxy, halogen, trihalomethyl, S(O)R, SO_2NRR', SO_3R, SR, NO_2, NRR', OH, CN, C(O)R, OC(O)R, NHC(O)R, $(CH_2)_nCO_2R$, CONRR', and $(CH_2)_nONRR'$;

A is selected from the group consisting of 4,5,6,7-tetrahydroindole, thiophene, pyrrole, pyrazole, imidazole, 1,2,3-triazole, 1,2,4-triazole, oxazole, isoxazole, thiazole, isothiazole, 2-sulfonylfuran, 4-alkylfuran, 1,2,3-oxadiazole, 1,2,4-oxadiazole, 1,2,5-oxadiazole, 1,3,4-oxadiazole, 1,2,3,4,-oxatriazole, 1,2,3,5-oxatriazole, 1,2,3-thiadiazole, 1,2,4-thiadiazole, 1,2,5-thiadiazole, 1,3,4-thiadaizole, 1,2,3,4-thiatriazole, 1,2,3,5-thiatriazole, and tetrazole, wherein said group is optionally substituted with one or more substituents selected from the group consisting of alkyl, alkoxy, aryl, aryloxy, alkaryl, alkaryloxy, halogen, trihalomethyl, S(O)R, SO_2NRR', SO_3R, SR, NO_2, NRR', OH, CN, C(O)R, OC(O)R, NHC(O)R, $(CH_2)_nCO_2R$, CONRR', and $(CH_2)_nONRR'$;

C4 Cont.

n is 0-3;

R is selected from the group consisting of H, alkyl, and aryl; and

R' is selected from the group consisting of H, alkyl, and aryl, wherein said alkyl is optionally substituted with a six-membered heteroaliphatic ring, and wherein said six-membered ring is optionally substituted at one or more positions with substituents selected from the group consisting of alkyl, alkoxy, halogen, trihalomethyl, NO_2, and $(CH_2)_nCO_2R$.

17. (NEW) A method of inhibiting VEGF, FGF, or PDGF stimulated cell proliferation in vein endothelial cells or smooth muscle cells *in vitro*, comprising:

a) contacting said cells with one more compounds of formula I,

wherein said composition optionally includes one more pharmaceutically acceptable excipients in at least one of parenteral, oral, or topical formulation:

(I) 

wherein,

R_1 is H or alkyl;

R_2 is O or S;

R_3 is H;

C4
Cont

R_4, R_5, R_6, and R_7 are each independently selected from the group consisting of hydrogen alkyl, alkoxy, aryl, aryloxy, alkaryl, alkaryloxy, halogen, trihalomethyl, S(O)R, SO_2NRR', SO_3R, SR, NO_2, NRR', OH, CN, C(O)R, OC(O)R, NHC(O)R, $(CH_2)_nCO_2R$, CONRR', and $(CH_2)_nONRR'$;

A is selected from the group consisting of 4,5,6,7-tetrahydroindole, thiophene, pyrrole, pyrazole, imidazole, 1,2,3-triazole, 1,2,4-triazole, oxazole, isoxazole, thiazole, isothiazole, 2-sulfonylfuran, 4-alkylfuran, 1,2,3-oxadiazole, 1,2,4-oxadiazole, 1,2,5-oxadiazole, 1,3,4-oxadiazole, 1,2,3,4,-oxatriazole, 1,2,3,5-oxatriazole, 1,2,3-thiadiazole, 1,2,4-thiadiazole, 1,2,5-thiadiazole, 1,3,4-thiadaizole, 1,2,3,4-thiatriazole, 1,2,3,5-thiatriazole, and tetrazole, wherein said group is optionally substituted with one or more substituents selected from the group consisting of alkyl, alkoxy, aryl, aryloxy, alkaryl, alkaryloxy, halogen, trihalomethyl, S(O)R, SO_2NRR', SO_3R, SR, NO_2, NRR', OH, CN, C(O)R, OC(O)R, NHC(O)R, $(CH_2)_nCO_2R$, CONRR', and $(CH_2)_nONRR'$;

n is 0-3;

R is selected from the group consisting of H, alkyl, and aryl; and

R' is selected from the group consisting of H, alkyl, and aryl, wherein said alkyl is optionally substituted with a six-membered heteroaliphatic ring, and wherein said six-membered ring is optionally substituted at one or more positions with substituents selected from the group consisting of alkyl, alkoxy, halogen, trihalomethyl, NO_2, and $(CH_2)_nCO_2R$;

C4

COOH

b) measuring the activity of VEGF, FGF, or PDGF; and

c) comparing said activity of VEGF, FGF, or PDGF to cells that have not been contacted with one more compounds of formula I.